To organize and conduct a clinical trial (СT) at a high level, it is necessary to continuously monitor its quality, as the occurrence of non-conformances can threaten health and safety of the trial subjects, as well as lead to CT data loss or their unreliability. In general, for the effective CT quality control, it is expedient to continuously improve the quality management system of all parties who participate in the CT, including at the clinical site. Current regulatory requirements include an indication of the need for a continuous process of the quality management system improvement to ensure the proper level of the process performance, in particular, the system of non-conformances correction and prevention. The aim of this work was to...
The use of organo-iodinated contrast media (CM) in diagnostics and intervention has increased in the...
International audienceBackground aims: According to European Directive 2001/83/EC, chimeric antigen ...
The implementation of a complex risk-oriented approach at all stages of drug development, including ...
At the modern stage of the pharmaceutical industry development quality risk management becomes an in...
Risk management is the systematic application of management policies, procedures, and practices to t...
To ensure the quality assurance of CT-examinations, it is necessary to obtain the high-quality diagn...
Abstract BACKGROUND: An important point in improving laboratory quality is the definition of some i...
Clinical trials serve a key role in drug development by providing scientific knowledge on the risks ...
The necessity of ensuring the implementation of planned objectives concerning quality, costs and tim...
The article analyses main quality assurance requirements for organizations that participate in precl...
Clinical laboratory tests ensure approximately 70% of the medical decisions, so that the time until ...
The article reviews the regulatory framework in the field of regulating the activities of laboratori...
The formulation of a correct diagnosis and the prescription of adequate therapies represent key aspe...
on GCP). European Directive 2001/20 on GCP and CTs has been widely criticized by a large portion of ...
The conduct of clinical trials falls within a strict regulatory framework. The objective of the rou...
The use of organo-iodinated contrast media (CM) in diagnostics and intervention has increased in the...
International audienceBackground aims: According to European Directive 2001/83/EC, chimeric antigen ...
The implementation of a complex risk-oriented approach at all stages of drug development, including ...
At the modern stage of the pharmaceutical industry development quality risk management becomes an in...
Risk management is the systematic application of management policies, procedures, and practices to t...
To ensure the quality assurance of CT-examinations, it is necessary to obtain the high-quality diagn...
Abstract BACKGROUND: An important point in improving laboratory quality is the definition of some i...
Clinical trials serve a key role in drug development by providing scientific knowledge on the risks ...
The necessity of ensuring the implementation of planned objectives concerning quality, costs and tim...
The article analyses main quality assurance requirements for organizations that participate in precl...
Clinical laboratory tests ensure approximately 70% of the medical decisions, so that the time until ...
The article reviews the regulatory framework in the field of regulating the activities of laboratori...
The formulation of a correct diagnosis and the prescription of adequate therapies represent key aspe...
on GCP). European Directive 2001/20 on GCP and CTs has been widely criticized by a large portion of ...
The conduct of clinical trials falls within a strict regulatory framework. The objective of the rou...
The use of organo-iodinated contrast media (CM) in diagnostics and intervention has increased in the...
International audienceBackground aims: According to European Directive 2001/83/EC, chimeric antigen ...
The implementation of a complex risk-oriented approach at all stages of drug development, including ...